Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study
Authors:
Open Access
- 14 March 2016
- journal article
- research article
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 3 (1) , 99-105
Abstract
Background Azithromycin has been associated with abnormalities of cardiac repolarization and development of torsades de pointes. Observational data suggest that the risk of death from cardiovascular causes is increased in patients taking azithromycin. Little is known regarding the risk of ventricular arrhythmia in patients with prolongation of the corrected QT interval who receive azithromycin. Objective The purpose of this study was to determine the incidence of sustained ventricular tachycardia in patients with prolonged corrected QT (QTc) who subsequently received azithromycin. Methods We performed a retrospective cohort analysis of the incidence of sustained ventricular tachycardia in patients with prolonged QTc (greater than 450 ms) who successively received intravenous (IV) and/or oral azithromycin. Patients hospitalized in a tertiary care teaching hospital between November 2009 and June 2012 were included in the study. The primary outcome was sustained ventricular tachycardia documented in patients on telemetry. Results Of the 103 patients enrolled in the study, only one patient experienced the primary outcome (0.97 %). The event occurred 1 day after the administration of a single dose of 500 mg IV azithromycin. Conclusion The risk of sustained ventricular tachycardia was 0.97 % in our cohort of patients with prolonged QTc who subsequently received azithromycin. Given the small size of this study, additional research is needed to determine the true incidence of arrhythmia in the population.Keywords
This publication has 39 references indexed in Scilit:
- Azithromycin and risk of sudden cardiac death: Guilty as charged or falsely accused?Cleveland Clinic Journal of Medicine, 2013
- Azithromycin and the Risk of Cardiovascular DeathNew England Journal of Medicine, 2012
- Mechanisms, Risk Factors, and Management of Acquired Long QT Syndrome: A Comprehensive ReviewThe Scientific World Journal, 2012
- Drug‐induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)Pharmacoepidemiology and Drug Safety, 2009
- Antimicrobial-Associated QT Interval Prolongation: Pointes of InterestClinical Infectious Diseases, 2006
- Update of the Clinical Impact and Issues Surrounding Dofetilide (Tikosyn) TherapyAACN Advanced Critical Care, 2006
- QT Prolongation with Antimicrobial AgentsDrugs, 2004
- Concomitant Risk Factors in Reports of Torsades de Pointes Associated with Macrolide Use: Review of the United States Food and Drug Administration Adverse Event Reporting SystemClinical Infectious Diseases, 2002
- Evaluation of Drug-Induced QT Interval ProlongationDrug Safety, 2001
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000